engleski

A recombinant bivalent protein that links innate and adoptive immune mechanisms might serve in the treatment of viral infection

HCMV is an important human pathogen in immunocompromised and immunologically immature individuals. Up to 75% of patients undergoing solid organ transplantation suffer from the primary infection or reactivation of latent HCMV infection despite the use of prophylactic and preemptive antiviral therapy. Therefore, a recombinant fusion protein has been developed and is being tested in the MCMV infection therapy model. Like many other herpesviruses, CMV possesses numerous mechanisms aimed at avoiding or compromising the host's immune response, among others, downregulation of ligands for the activating NK cell receptor NKG2D. The developed protein's therapeutic potential lies in its ability to bypass the components of innate and specific immune responses. The protein is composed of the ectodomain of a high affinity ligand for the NKG2D receptor, MULT-1, and variable regions of the immunoglobulin specific for the viral protein expressed on the surface of infected cells, gB. It is expected that such molecule, when applied in vivo, can mediate a specific activation of NK cells leading to the control of viral infection.

recombinant protein; monoclonal antibody; viral infection

nije evidentirano